EnovisENOV
About: Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention & Recovery (P&R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention & Recovery segment.
Employees: 6,550
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
297% more call options, than puts
Call options by funds: $73.6M | Put options by funds: $18.6M
55% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 82
1.23% more ownership
Funds ownership: 109.34% [Q1] → 110.57% (+1.23%) [Q2]
1% less funds holding
Funds holding: 284 [Q1] → 282 (-2) [Q2]
5% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 44
27% less capital invested
Capital invested by funds: $3.73B [Q1] → $2.73B (-$997M) [Q2]
80% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 1 (-4) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
JMP Securities David Turkaly 45% 1-year accuracy 10 / 22 met price target | 51%upside $62 | Market Outperform Initiated | 3 Oct 2024 |
Evercore ISI Group Vijay Kumar 74% 1-year accuracy 28 / 38 met price target | 41%upside $58 | Outperform Maintained | 1 Oct 2024 |
JP Morgan Robbie Marcus 47% 1-year accuracy 9 / 19 met price target | 22%upside $50 | Neutral Maintained | 8 Aug 2024 |
Needham Mike Matson 56% 1-year accuracy 64 / 115 met price target | 58%upside $65 | Buy Maintained | 8 Aug 2024 |